These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 38322348)

  • 1. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.
    Peng X; Hu Z; Zeng L; Zhang M; Xu C; Lu B; Tao C; Chen W; Hou W; Cheng K; Bi H; Pan W; Chen J
    Acta Pharm Sin B; 2024 Feb; 14(2):533-578. PubMed ID: 38322348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degraders in epigenetic therapy: PROTACs and beyond.
    Dai XJ; Ji SK; Fu MJ; Liu GZ; Liu HM; Wang SP; Shen L; Wang N; Herdewijn P; Zheng YC; Wang SQ; Chen XB
    Theranostics; 2024; 14(4):1464-1499. PubMed ID: 38389844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the PRMT6 modulators in cancer treatment: Current progress and emerged opportunity.
    Peng J; Ni B; Li D; Cheng B; Yang R
    Eur J Med Chem; 2024 Dec; 279():116857. PubMed ID: 39276585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key Considerations in Targeted Protein Degradation Drug Discovery and Development.
    Qin L; Dai H; Wang J
    Front Chem; 2022; 10():934337. PubMed ID: 35978859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major Advances in Emerging Degrader Technologies.
    Luo H; Wu L; He Y; Qin C; Tang X
    Front Cell Dev Biol; 2022; 10():921958. PubMed ID: 35813205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective.
    Webb T; Craigon C; Ciulli A
    Bioorg Med Chem Lett; 2022 May; 63():128653. PubMed ID: 35257896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
    Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of natural product-based targeted protein degraders as anticancer agents.
    Chen C; Feng Y; Zhou C; Liu Z; Tang Z; Zhang Y; Li T; Gu C; Chen J
    Bioorg Chem; 2024 Dec; 153():107772. PubMed ID: 39243739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer.
    Chen QH; Munoz E; Ashong D
    Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrophobic tagging of small molecules: an overview of the literature and future outlook.
    Zhou Y; Zhou F; Xu S; Shi D; Ding D; Wang S; Poongavanam V; Tang K; Liu X; Zhan P
    Expert Opin Drug Discov; 2024 Jul; 19(7):799-813. PubMed ID: 38825802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of PRMT1 modulators: Inhibitors and degraders.
    Wu J; Li D; Wang L
    Eur J Med Chem; 2024 Dec; 279():116887. PubMed ID: 39316844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
    Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
    J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of a PROTAC Mutant Huntingtin Degrader into Small-Molecule Hydrophobic Tags Focusing on Drug-like Properties.
    Hirai K; Yamashita H; Tomoshige S; Mishima Y; Niwa T; Ohgane K; Ishii M; Kanamitsu K; Ikemi Y; Nakagawa S; Taguchi H; Sato S; Hashimoto Y; Ishikawa M
    ACS Med Chem Lett; 2022 Mar; 13(3):396-402. PubMed ID: 35300080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC-targeting epigenetic modulators for cancer immunotherapy.
    Cheng B; Pan W; Xiao Y; Ding Z; Zhou Y; Fei X; Liu J; Su Z; Peng X; Chen J
    Eur J Med Chem; 2024 Feb; 265():116129. PubMed ID: 38211468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTACs Targeting Epigenetic Proteins.
    Zhang C; He Y; Sun X; Wei W; Liu Y; Rao Y
    Acta Mater Med; 2023 Oct; 2(4):409-429. PubMed ID: 39221114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy.
    Peng X; Pan W; Jiang F; Chen W; Qi Z; Peng W; Chen J
    Pharmacol Res; 2022 Dec; 186():106529. PubMed ID: 36328301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic approaches advancing targeted protein degradation.
    Sathe G; Sapkota GP
    Trends Pharmacol Sci; 2023 Nov; 44(11):786-801. PubMed ID: 37778939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
    Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
    Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective.
    Chang X; Qu F; Li C; Zhang J; Zhang Y; Xie Y; Fan Z; Bian J; Wang J; Li Z; Xu X
    Med Res Rev; 2024 Jul; 44(4):1727-1767. PubMed ID: 38314926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.